Cape Investment Advisory Inc. Has $695,000 Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Cape Investment Advisory Inc. trimmed its holdings in Johnson & Johnson (NYSE:JNJFree Report) by 21.1% during the third quarter, Holdings Channel reports. The institutional investor owned 4,462 shares of the company’s stock after selling 1,194 shares during the quarter. Cape Investment Advisory Inc.’s holdings in Johnson & Johnson were worth $695,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. State Street Corp raised its holdings in shares of Johnson & Johnson by 1.1% in the second quarter. State Street Corp now owns 141,833,756 shares of the company’s stock valued at $23,476,323,000 after purchasing an additional 1,568,633 shares during the last quarter. Moneta Group Investment Advisors LLC raised its holdings in shares of Johnson & Johnson by 90,144.4% in the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Johnson & Johnson by 2.0% in the second quarter. Geode Capital Management LLC now owns 49,697,798 shares of the company’s stock valued at $8,203,608,000 after purchasing an additional 990,298 shares during the last quarter. Morgan Stanley raised its holdings in shares of Johnson & Johnson by 12.0% in the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after purchasing an additional 4,521,062 shares during the last quarter. Finally, Capital International Investors raised its holdings in shares of Johnson & Johnson by 62.7% in the second quarter. Capital International Investors now owns 27,825,795 shares of the company’s stock valued at $4,605,627,000 after purchasing an additional 10,724,110 shares during the last quarter. 68.40% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on JNJ shares. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday. UBS Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $167.00 to $180.00 in a report on Friday, December 1st. Barclays raised their price objective on shares of Johnson & Johnson from $158.00 to $162.00 and gave the stock an “equal weight” rating in a report on Thursday, October 12th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Wednesday, January 24th. Eight investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $176.14.

Check Out Our Latest Report on Johnson & Johnson

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $158.07 on Wednesday. The company has a quick ratio of 0.96, a current ratio of 1.21 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $380.52 billion, a PE ratio of 11.45, a P/E/G ratio of 2.63 and a beta of 0.53. Johnson & Johnson has a twelve month low of $144.95 and a twelve month high of $175.97. The company has a 50-day moving average price of $158.08 and a two-hundred day moving average price of $159.05.

Johnson & Johnson (NYSE:JNJGet Free Report) last released its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 EPS for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 36.75%. The company had revenue of $21.40 billion during the quarter, compared to analyst estimates of $21.02 billion. During the same period last year, the business earned $2.35 earnings per share. Johnson & Johnson’s revenue was down 9.7% compared to the same quarter last year. Equities analysts forecast that Johnson & Johnson will post 10.66 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 5th. Stockholders of record on Tuesday, February 20th will be given a $1.19 dividend. The ex-dividend date is Friday, February 16th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 3.01%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 34.47%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.